SAN DIEGO, Jan. 16 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc.
(NYSE: BMR) today announced that its underwriters have exercised their
over-allotment option in full to purchase an additional 1,200,000 shares of
7.375% Series A Cumulative Redeemable Preferred Stock at $25.00 per share in
connection with BioMed's previously announced offering that priced on
January 10, 2007. The offering is expected to close on or about January 18,
2007. In total, the company will sell 9,200,000 shares of series A preferred
stock, raising gross offering proceeds of approximately $230.0 million.
Wachovia Capital Markets, LLC, Morgan Stanley & Co. Incorporated and
Raymond James & Associates, Inc. are joint-bookrunners for the offering, and
KeyBanc Capital Markets, a division of McDonald Investments Inc., Robert W.
Baird & Co. Incorporated, Credit Suisse Securities (USA) LLC, Friedman,
Billings, Ramsey & Co., Inc., RBC Dain Rauscher Inc. and Stifel, Nicolaus &
Company, Incorporated are co-managers.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the offered shares, nor shall there be
any sale of such shares in any state in which such offer, solicitation, or
sale would be unlawful prior to registration or qualification under the
securities laws of such state. The offering of BioMed's series A preferred
stock is being made only by means of a prospectus and a related prospectus
supplement, copies of which may be obtained by contacting Wachovia Securities,
ATTN: Prospectus Department, 8739 Research Drive, Charlotte, North Carolina
28262, or by calling 866-289-1262.
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused
on Providing Real Estate to the Life Science Industry(TM). The company's
tenants primarily include biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry, and its properties and primary
acquisition targets are generally located in markets with well established
reputations as centers for scientific research, including Boston, San Diego,
San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey.
BioMed's real estate portfolio consists of 56 properties, representing
92 buildings with approximately 7.9 million rentable square feet in each of
the major life science markets in the United States. Additional information
is available at www.biomedrealty.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These
risks and uncertainties include, without limitation: general risks affecting
the real estate industry (including, without limitation, the inability to
enter into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing and the use of debt to fund acquisitions and developments;
failure to manage effectively the company's growth and expansion into new
markets, or to complete or integrate acquisitions successfully; risks and
uncertainties affecting property development and construction; risks
associated with downturns in the national and local economies, increases in
interest rates, and volatility in the securities markets; potential liability
for uninsured losses and environmental contamination; risks associated with
the company's potential failure to qualify as a REIT under the Internal
Revenue Code of 1986, as amended, and possible adverse changes in tax and
environmental laws; and risks associated with the company's dependence on key
personnel whose continued service is not guaranteed. For a further list and
description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q.
The company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE BioMed Realty Trust, Inc.
CONTACT: Kent Griffin, Chief Financial Officer of BioMed Realty Trust,
Web site: http://www.biomedrealty.com